-
公开(公告)号：US20200041430A1
公开(公告)日：2020-02-06
申请号：US16339789
申请日：2017-10-06
Applicant: Wake Forest University Health Sciences
Inventor： F. Scott Gayzik , Ryan D.M. Packett , Philip J. Brown , Gautam Popli , Megan Fritz
IPC: G01N25/00
Abstract: The present invention provides devices, systems, and methods for using them to monitor therapeutic cooling of blood perfused tissues or organs such as the brain. In one embodiment, the invention comprises a device for evaluating tissue cooling comprising a container that contains a polymer-fluid matrix having a thermal cooling property that is substantially similar to a tissue or organ such as a human brain. In another embodiment, the invention comprises a system for evaluating tissue cooling comprising: (a) a device for evaluating tissue cooling as described above and (b) a warm loop. In another embodiment, the invention comprises a method for evaluating a technique for cooling a tissue or organ comprising (a) providing a device comprising a container that contains a polymer-fluid matrix having a thermal cooling property that is substantially similar to a tissue or organ such as human brain, and (b) perfusing the polymer-fluid matrix with a fluid.
-
32.发明申请公开(公告)号：US20190375860A1
公开(公告)日：2019-12-12
申请号：US16311992
申请日：2017-06-30
Inventor： Mark E. WELKER , Emmanuel C. OPARA , Surya R. BANKS , Amber N. WEISSENENFLUH
Abstract: Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals.
-
33.发明申请公开(公告)号：US20190271042A1
公开(公告)日：2019-09-05
申请号：US16298592
申请日：2019-03-11
Applicant: ARTHUR KRIGSMAN , WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： Stephen Walker , Arthur Krigsman
IPC: C12Q1/6883 , A61K31/606 , G01N33/68 , A61K31/56 , A61K38/43
Abstract: The invention provides compositions and methods for identifying autism and autism spectrum disorders in humans. The invention also includes compositions and methods for identifying unique gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis.
-
公开(公告)号：US10377985B2
公开(公告)日：2019-08-13
申请号：US15875717
申请日：2018-01-19
Applicant: Wake Forest University Health Sciences
Inventor： Khalil Bitar
Abstract: Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets. The matrix compositions of the present invention can be used to tissue engineer transplantable innervated GI smooth muscle constructs to remedy aganglionic disorders.
-
公开(公告)号：US20190153057A1
公开(公告)日：2019-05-23
申请号：US16262195
申请日：2019-01-30
Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： WALDEMAR DEBINSKI , HETAL PANDYA , DENISE GIBO
IPC: C07K14/54 , C07K19/00 , A61K47/64 , C07K14/21 , C07K14/34 , G01N33/50 , G01N33/532 , G01N33/68 , C07K14/005 , C07K14/195
CPC classification number: C07K14/5437 , A61K38/00 , A61K47/642 , C07K14/005 , C07K14/195 , C07K14/21 , C07K14/34 , C07K19/00 , C07K2319/01 , C07K2319/09 , C07K2319/74 , G01N33/5008 , G01N33/5091 , G01N33/532 , G01N33/6869 , G01N2333/025 , G01N2333/195 , G01N2333/5437
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
-
Patent Agency Ranking
36.发明授权公开(公告)号：US10233224B2
公开(公告)日：2019-03-19
申请号：US15695392
申请日：2017-09-05
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Hetal Pandya , Denise Gibo
IPC: C12N15/24 , C07K14/54 , C07K19/00 , C07K14/21 , C07K14/34 , G01N33/50 , G01N33/532 , G01N33/68 , C07K14/005 , C07K14/195 , A61K47/64 , A61K38/00
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
-
公开(公告)号：US10207984B2
公开(公告)日：2019-02-19
申请号：US15145323
申请日：2016-05-03
Applicant: Emory University , Wake Forest University Health Sciences
Inventor： Huw M. L. Davies , Spandan Chennamadhavuni , Thomas J. Martin , Steven R. Childers
IPC: C07C229/46 , A61K31/195 , A61K45/06 , C07C227/16 , C07C67/313 , C07C69/757 , C07C227/04 , A61K31/216
Abstract: The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein.
-
公开(公告)号：US20190015190A1
公开(公告)日：2019-01-17
申请号：US16066492
申请日：2016-12-28
Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： Khalil BITAR
Abstract: Methods are disclosed for forming tissue engineered, tubular gut-sphincter complexes from intestinal circular smooth muscle cells, sphincteric smooth muscle cells and enteric neural progenitor cells. The intestinal smooth muscle cells and neural progenitor cells can be seeded on a mold with a surface texture that induces longitudinal alignment of the intestinal smooth muscle cells and co-cultured until an innervated aligned smooth muscle sheet is obtained. The innervated smooth muscle sheet can then be wrapped around a tubular scaffold to form an intestinal tissue construct. Additionally, the sphincteric smooth muscle cells and additional enteric neural progenitor cells can be mixed in a biocompatiable gel solution, and the gel and admixed cells applied to a mold having a central post such that the sphinteric smooth muscle and neural progenitor cells can be cultured to form an innervated sphincter construct around the mold post. This innervated sphincter construct can also be transferred to the tubular scaffold such that the intestinal tissue construct and sphincter construct contact each other, and the resulting combined sphincter and intestinal tissue constructs can be further cultured about the scaffold until a unified tubular gut-sphincter complex is obtained.
-
39.发明申请公开(公告)号：US20180369343A1
公开(公告)日：2018-12-27
申请号：US15856653
申请日：2017-12-28
Applicant: Wake Forest University Health Sciences , Genethon , Children's Medical Center Corporation
Inventor： Martin K. Childers , Alan H. Beggs , Ana Maria Buj Bello
CPC classification number: A61K38/465 , A61K48/005 , A61K48/0058 , C12N7/00 , C12N9/16 , C12N2750/14143 , C12Y301/03 , C12Y301/03064
Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.
-
公开(公告)号：US10123750B2
公开(公告)日：2018-11-13
申请号：US14759092
申请日：2014-01-03
Applicant: Wake Forest University Health Sciences
Inventor： Mark R. Witcher , Robert E. Hampson , Sam Deadwyler , Daniel E. Couture , Gautam Popli
IPC: A61B5/04 , A61B5/00 , A61B5/0476 , A61N1/05 , A61N1/36
Abstract: The present invention provides methods and devices for predicting, preventing, detecting and/or treating seizures. In some embodiments, the present invention provides methods/devices for predicting a seizure prior to its inception, wherein the seizure is predicted based upon neuronal activity in the CA3 region of a patient's hippocampus.
-
-
-
-
-
-
-
-
-
Search Results
514
records
(took 0.035 seconds)
